Dublin, May 11, 2020 (GLOBE NEWSWIRE) -- The "Metabolic Acidosis - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of metabolic acidosis, historical and forecasted epidemiology as well as the metabolic acidosis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.
The metabolic acidosis market report provides current treatment practices, emerging drugs, metabolic acidosis market share of the individual therapies, current and forecasted metabolic acidosis market size from 2017 to 2030 segmented by 10 emerging markets. The report also covers market drivers, market barriers and unmet medical needs to curate the best of the opportunities and evaluates the underlying potential of the market.
Treatment
It covers the details of conventional and current medical therapies available in the market for the treatment of metabolic acidosis. It also provides the country-wise treatment guidelines and algorithms across the 10 emerging markets.
The Metabolic Acidosis market report gives a thorough understanding of metabolic acidosis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
Epidemiology
Metabolic acidosis epidemiology segment provides insights about historical and current metabolic acidosis patient pool and forecasted trends for 10 emerging countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The total prevalent cases of metabolic acidosis patients were found to be more in males than in females in 10 EM during the study period 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted Metabolic Acidosis epidemiology segmented as Total Prevalent Population of CKD patients, Total Prevalent Population of Metabolic Acidosis in CKD patients, Gender-Specific Diagnosed Population of Metabolic Acidosis, Total Diagnosed Population of Metabolic Acidosis, and Total Treated Population of Metabolic Acidosis in 10EM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, Brazil, China, and Mexico from 2017 to 2030.
Country-Wise Epidemiology
The epidemiology section also provides the metabolic acidosis epidemiology data and key findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.
Drug Chapters
This segment of the metabolic acidosis report encloses the detailed analysis of current drug therapies and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the metabolic acidosis clinical trial details, expressive pharmacological actions, agreements and collaborations, approval and awards, advantages and disadvantages of each included drug, and the latest news and press releases.
There are no FDA-approved therapies for long-term treatment of metabolic acidosis in CKD patients; however oral alkali therapies such as sodium bicarbonate, sodium citrate, and potassium citrate/citric acid are currently prescribed by the nephrologists for treatment of metabolic acidosis.
Emerging Drugs
Veverimer (TRC101): Tricida
Veverimer, which is also known as TRC101, is a novel, nonabsorbed polymer that is designed for the treatment of metabolic acidosis by binding hydrochloric acid in the gastrointestinal tract and removing it from the body through excretion in the feces. It also helps in decreasing the total amount of acid in the body and increasing blood bicarbonate. Veverimer is administered orally as a suspension in water, and it is currently under assessment by the US Food and Drug Administration (FDA) for New Drug Application (NDA) assessment.
ADV7103: Advicenne Pharma
ADV7103 is a pioneering product with a prolonged-release formulation designed to maintain a sustained release over 12 h. The product was developed as a multi particulate formulation in 2mm granules that contains two active pharmaceutical ingredients. This drug molecule is tasteless and easy to administer orally in patients of all ages. It is an investigational drug designed to treat distal renal tubular acidosis (dRTA) in patients of all ages. In December 2019, Advicenne signed a supply agreement with the pharmaceutical contract development and manufacturing organization (CDMO) Elaiapharm Lundbeck for the manufacturing of its lead product ADV7103 with a view to its worldwide commercialization as a treatment for distal Renal Tubular Acidosis (dRTA).
Market Outlook
The metabolic acidosis market outlook helps to cultivate a detailed comprehension of the historical, current and forecasted market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for the better technology.
This segment gives a thorough detail of metabolic acidosis market trend of each late-stage pipeline therapy by evaluating their impact based on annual cost of treatment, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear picture of the market at first sight.
According to the report, the therapeutic market of Metabolic Acidosis in 10 emerging markets generated USD 483.62 million in 2017.
Key Findings
Reimbursement Scenario
Proactively approaching reimbursement can have a positive impact, not only during the late stages of product development but well after product launch as well. In the report, the publisher considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL Views
To keep up with current market trends, the publisher takes KOLs and SME's opinion working in and for metabolic acidosis domain through primary research to fill the data gaps, and validate the secondary research. Their opinion helps us to understand and verify current and emerging therapies treatment patterns or current market trends. It will also support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
The publisher performs Competitive and Market Intelligence analysis of the Metabolic Acidosis market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the availability of the data.
Scope of the Report
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/asvbjh
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900